Short-term, high-dose statins in the prevention of contrast-induced nephropathy: A systematic review and meta-analysis

Clinical Nephrology

Volumn 76, Issue 6, 2011, Pages 475-483

  Zhou, Y ^a   Yuan, W J ^a   Zhu, N ^a   Wang, L ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Contrast induced nephropathy; Meta analysis; Shortterm high dose statin; Systematic review

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; CONTRAST MEDIUM; CREATININE; PLACEBO; SIMVASTATIN;

CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SHORT COURSE THERAPY; STAGING; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

CONTRAST MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84855432039     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106950     Document Type: Review

References (37)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51: 1419-1428.
2. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004; 44: 1780-1785.
3. Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Media Econ. 2007; 10: 119-134.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259-2264.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996; 275: 1489-1494.
6. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990; 258: F115-F120.
7. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int. 1992; 41: 1408-1415.
8. Dawnay AB, Thornley C, Nockler I, Webb JA, Cattell WR. Tamm-Horsfall glycoprotein excretion and aggregation during intravenous uroraphy. Relevance to acute renal failure. Invest Radiol. 1985; 20: 53-57.
9. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997; 30: 82-86.
10. Zager RA, Johnson ACM, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003; 64: 128-139.
11. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103: 368-375.
12. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999; 33: 1756-1824.
13. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008; 295: F53-F59.
14. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-2016.
15. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009; 15.
16. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004; 62: 273-278.
17. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005; 118: 843-849.
18. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, Di Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008; 101: 279-285.
19. Higgins JPT, Green S,eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
20. Chen GL, Su JZ. Atorvastatins attenuated contrast induced renal function damage. Chin J Cardiol. 2009; 37: 389-393.
21. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatins in patients with a CKD stage ≤ 3 undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J. 2008; 155: 499.e1-499.e8.
22. Jia XW, Fu XH, Zhang J, Gu XS, Xue L, Fan W, Hao GZ, Jiang YF, Wu WL, Li SQ. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104: 519-524.
23. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010; 105: 288-292.
24. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R. Efficacy of shortterm high-dose atorvastatins for prevention of contrast-induced nephropathy in patients undergoing doronary angiography. Angiology. 2010; 67: 1-4.
25. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatins on preventing contrast induced nephropathy in patients underwent coronary angiography. Chin J Cardiol. 2009; 37: 394-398.
26. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney Int. 2006; 69 (Suppl. 100): 8-10.
27. Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol. 2001; 280: 61-70.
28. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998; 32: 64-71.
29. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001; 49: 281-287.
30. Chello M, Mastroroberto P, Patti G, D'Ambrosio A, Morichetti MC, Di Sciascio G, Covino E. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart. 2003; 89: 538-543.
31. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Highdose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003; 108: 1560-1566.
32. Ceriello A. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol. 2006; 17: 510-518.
33. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87: 1451-1458.
34. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002; 45: 147-154.
35. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA; CIN Consensus Working Panel. Pathophysiology of contrastinduced nephropathy. Am J Cardiol. 2006; 98 (suppl): 14-20.
36. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-184.
37. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006; 354: 379-386.